Financial Architects Inc Has $49,000 Holdings in Pacira Pharmaceuticals Inc (PCRX)

Share on StockTwits

Financial Architects Inc lowered its position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 21.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,130 shares of the company’s stock after selling 310 shares during the quarter. Financial Architects Inc’s holdings in Pacira Pharmaceuticals were worth $49,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the business. Legacy Capital Partners Inc. raised its position in shares of Pacira Pharmaceuticals by 1.0% in the fourth quarter. Legacy Capital Partners Inc. now owns 48,008 shares of the company’s stock worth $2,065,000 after acquiring an additional 475 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Pacira Pharmaceuticals by 22.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,950 shares of the company’s stock worth $127,000 after acquiring an additional 538 shares during the period. DekaBank Deutsche Girozentrale raised its position in shares of Pacira Pharmaceuticals by 7.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 20,548 shares of the company’s stock worth $943,000 after acquiring an additional 1,393 shares during the period. Raymond James & Associates raised its position in shares of Pacira Pharmaceuticals by 21.7% in the second quarter. Raymond James & Associates now owns 21,611 shares of the company’s stock worth $693,000 after acquiring an additional 3,850 shares during the period. Finally, Russell Investments Group Ltd. raised its position in shares of Pacira Pharmaceuticals by 7.3% in the third quarter. Russell Investments Group Ltd. now owns 60,715 shares of the company’s stock worth $2,970,000 after acquiring an additional 4,105 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

A number of research analysts have weighed in on PCRX shares. ValuEngine upgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Mizuho restated a “hold” rating and set a $43.00 price target on shares of Pacira Pharmaceuticals in a research report on Thursday, November 1st. Piper Jaffray Companies set a $55.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. Needham & Company LLC set a $60.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. Finally, JMP Securities upped their price target on shares of Pacira Pharmaceuticals from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, November 1st. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $54.31.

PCRX opened at $37.58 on Friday. Pacira Pharmaceuticals Inc has a twelve month low of $26.95 and a twelve month high of $55.00. The company has a debt-to-equity ratio of 0.95, a current ratio of 8.66 and a quick ratio of 7.83. The stock has a market cap of $1.54 billion, a P/E ratio of -64.79 and a beta of 1.55.

In other Pacira Pharmaceuticals news, CEO David M. Stack sold 15,000 shares of the stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $47.39, for a total value of $710,850.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andreas Wicki sold 70,498 shares of the stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $47.34, for a total transaction of $3,337,375.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,503 shares of company stock valued at $5,001,639. 5.90% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This news story was reported by Macon Daily and is the sole property of of Macon Daily. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://macondaily.com/2019/02/09/financial-architects-inc-has-49000-holdings-in-pacira-pharmaceuticals-inc-pcrx.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

See Also: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply